A Pill in a World of Injections
For years, the most effective weight-loss medications, known as GLP-1 agonists, have come with a catch: they require injections. Drugs like Ozempic and Wegovy have transformed the management of type 2 diabetes and obesity, but the need for weekly shots
is a barrier for many. Enter orforglipron, an experimental drug from Eli Lilly. Its biggest selling point is its form: a once-daily tablet. Unlike older oral medications that have complex rules, orforglipron is a 'small molecule' drug designed to be easily absorbed by the gut, meaning it can be taken without special timing around meals or water intake. This convenience, combined with its potential to be cheaper to manufacture, has positioned it as a significant new contender in the multi-billion dollar weight-loss market.
The Promise: What the Trials Show
Recent Phase 3 clinical trials have generated considerable buzz, and for good reason. In a head-to-head study against the oral version of semaglutide (the active ingredient in Ozempic and Wegovy), orforglipron was found to be superior at both lowering blood sugar and promoting weight loss in people with type 2 diabetes. In one 52-week trial, participants on the highest dose of orforglipron lost an average of 9.2% of their body weight (around 9 kg), compared to 5.3% (around 5 kg) for those on oral semaglutide. Another trial focused on patients with obesity but without diabetes showed a mean weight reduction of 12.4% over 72 weeks. These numbers are statistically significant and demonstrate that the drug is highly effective.
The Reality: Side Effects and Dropouts
However, effectiveness is only one part of the story. The primary concern with orforglipron is its tolerability. Like other drugs in its class, it comes with a significant risk of gastrointestinal side effects, including nausea, vomiting, and diarrhea. In the head-to-head trial, these symptoms were more common with orforglipron; around 59% of participants reported them, compared to 37–45% on oral semaglutide. This led to a higher discontinuation rate. Approximately 10% of participants on orforglipron stopped the treatment due to adverse effects, more than double the rate for those taking semaglutide. This suggests that while orforglipron may be more potent, that potency comes at the cost of being harder for some patients to tolerate long-term.
Context and the Path to Approval in India
It's important to put these findings in context. The weight-loss results, while impressive for a pill, are still generally less than those seen with powerful injectable drugs. But the convenience of a daily tablet could make it a preferred option for many. Eli Lilly is banking on this, with plans to launch the drug in India, a market that heavily favours oral medications. Following US approval in April 2026 under the brand name Foundayo, the company has already received a positive recommendation from India's Central Drugs Standard Control Organisation (CDSCO). This nod, based on global trials that included Indian patients, came with conditions: the drug must be prescribed by a specialist and the company must conduct a Phase IV trial to monitor its long-term safety and effectiveness in the Indian population. A launch could potentially happen in the second half of 2026.
